# A Phase II Study of CCX282-B in Patients With Celiac Disease

> **NCT00540657** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 90 (estimated)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** CCX282-B
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00540657
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-06
- **Final completion:** 2008-07
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540657, "A Phase II Study of CCX282-B in Patients With Celiac Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00540657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*